Denali Therapeutics Inc. Annual Income Tax Expense (Benefit) in USD from 2017 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Denali Therapeutics Inc. annual/quarterly Income Tax Expense (Benefit) history and growth rate from 2017 to 2023.
  • Denali Therapeutics Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2023 was $0.000.
  • Denali Therapeutics Inc. annual Income Tax Expense (Benefit) for 2023 was $30K, a 42.9% increase from 2022.
  • Denali Therapeutics Inc. annual Income Tax Expense (Benefit) for 2022 was $21K.
  • Denali Therapeutics Inc. annual Income Tax Expense (Benefit) for 2021 was -$575K, a 170% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $30K +$9K +42.9% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
2022 $21K +$596K Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 -$575K -$1.4M -170% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 $823K +$1.17M Jan 1, 2020 Dec 31, 2020 10-K 2023-02-27
2019 -$351K -$351K Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $0 $0 Jan 1, 2018 Dec 31, 2018 10-K 2021-02-26
2017 $0 Jan 1, 2017 Dec 31, 2017 10-K 2020-02-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.